MAPT and Alzheimer disease: This can be achieved with positron emission tomography (PET) tracers that bind to hyper-phosphorylated tau proteins, such as [18F]MK-6240 which has sub-nanomolar affinity for NFTs and has been studied and validated recently in healthy control (HC), mild cognitive impairment (MCI), and AD subjects [3–7].